Genetic epidemiology of cutaneous melanoma; A Global Perspective

Archives of Dermatology

Volumn 137, Issue 11, 2001, Pages 1493-1496

  Goldstein, A M ^a   Tucker, M A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROTEIN CDKN2A; UNCLASSIFIED DRUG;

BASAL CELL CARCINOMA; CLINICAL FEATURE; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; GENETIC ANALYSIS; GENETIC EPIDEMIOLOGY; GENETIC PREDISPOSITION; HUMAN; MELANOMA; PRIORITY JOURNAL; RADIATION EXPOSURE; REVIEW; SQUAMOUS CELL CARCINOMA; ULTRAVIOLET RADIATION;

DNA MUTATIONAL ANALYSIS; GENES, P16; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MELANOMA; RESEARCH; SKIN NEOPLASMS;

EID: 0035169350     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Cutaneous malignant melanoma
2. Clinically recognized dysplastic nevi: A central risk factor for cutaneous melanoma
3. Familial melanoma and its management
4. Comparison of nonfamilial and familial melanoma
5. Familial malignant melanoma
6. Heterogeneity of melanoma risk in families of melanoma patients
7. A cell cycle regulator potentially involved in genesis of many tumor types
8. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
9. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
10. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways
11. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53
12. A p16INK4a insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
13. Chromosomal mapping of human cDK2, CDK4, and CDK5 cell-cycle kinase genes
14. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
15. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France
16. Genotype-phenotype relationships in American melanoma-prone families with CDKN2A and CDK4 mutations
17. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium
18. CDKN2A mutations in multiple primary melanomas
19. CDKN2A germline mutations in U.K. Patients with familial melanoma and multiple primary melanomas
20. CDKN2A (p16INK4a) and CDK4 mutation analysis in 131 Australian melanoma probands: Effect of family history and multiple primary melanomas
21. Mutation of the CDKN2A 5′ UTR creates an aberrant initiation codon and predisposes to melanoma
22. Homozygotes for CDKN2(p16) germline mutation in Dutch familial melanoma kindreds
23. Haplotype analysis and age estimation of the 113insR CDKN2A founder mutation in Swedish melanoma families
24. Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: Evidence for common founders and independent mutations
25. A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families
26. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations
27. Familial melanoma and pancreatic cancer
28. Characterization of Ligurian melanoma families and risk of occurrence of other neoplasia
29. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families
30. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors
31. ARF, and CDK4 alterations in familial glioma
32. ARF but not CDKN2A in a melanoma-neural system tumor syndrome family
33. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development
34. Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility